Long-term outcomes after surgical resection of pancreatic metastases from renal Clear-cell carcinoma

Boubaddi, Mehdi; Marichez, Arthur; Adam, Jean Philippe; Chiche, Laurence; Laurent, Christophe

doi:10.1016/j.ejso.2024.107960

European Journal of Surgical Oncology

2024

DOI: 10.1016/j.ejso.2024.107960

|View full text |Cite

Long-term outcomes after surgical resection of pancreatic metastases from renal Clear-cell carcinoma

Mehdi Boubaddi,

Arthur Marichez,

Jean Philippe Adam

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

A pooled analysis of pancreatic resection for metastatic renal cell carcinoma

Zhou,

Wang,

Chen

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

BackgroundPancreatic metastasis from renal cell carcinoma (PMRCC) is unusual and there is no consensus on its treatment. The present study aims to evaluate the clinical outcomes of surgical resection for PMRCC.MethodsPubMed and Web of Science were searched for Eligible studies from January 1980 to January 2024. Individual-patient data were pooled.ResultsA total of 436 participants were identified. The morbidity and 90-day mortality were 38.1% and 3.4%, respectively. Post-pancreatectomy recurrence occurred in 44.1% of the patients. The overall median survival was 116 months, with a 3-, 5- and 10-year survival rate of 85.3%, 76.6%, and 46.5% respectively. On univariate analysis, repeat metastasectomy was associated with a significantly better prognosis (P =0.003).ConclusionThese data suggest that surgical resection is a safe and effective therapeutic option for PMRCC. Repeat metastasectomy is positively suggested for recurrent disease provided all metastases can be removed curatively. Systematic review registrationhttps://www.crd.york.ac.uk/prospero/, identifier CRD42024525218.

show abstract

A pooled analysis of pancreatic resection for metastatic renal cell carcinoma

Zhou,

Wang,

Chen

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

show abstract

Surgery for an Uncommon Pathology: Pancreatic Metastases from Renal Cell Carcinoma—Indications, Type of Pancreatectomy, and Outcomes in a Single-Center Experience

Matei,

Ciurea,

Herlea

et al. 2024

Medicina

View full text Add to dashboard Cite

Background and Objectives: The role of surgery in pancreatic metastases of renal cell carcinoma (PM_RCC) is highly controversial, particularly in the context of modern systemic therapies and the conflicting results of studies published so far. This study aims to explore a single surgical center experience (including mainly pancreatic resections) regarding the indications, the type of pancreatectomies, and early and long-term outcomes for PM_RCC. Materials and Methods: The data of all patients with surgery for PM_RCC (from 1 January 2002 to 31 December 2023) were retrospectively assessed, and potential predictors of survival were explored. Results: 20 patients underwent surgery for PM_RCC (pancreatectomies—95%). Metachronous PM_RCC was 90%, with a median interval between the initial nephrectomy and PM_RCC occurrence of 104 months. For elective pancreatectomies, the overall and severe morbidity and mortality rates were 24%, 12%, and 0%, respectively; 32% of patients underwent non-standardized pancreatic resections. The median survival of patients with negative resection margins was 128 months after pancreatectomies, with an 82% 5-year survival rate. Left kidney RCC and the body/tail PM_RCC were favorable prognostic factors for the overall survival after pancreatectomies for PM_RCC. Body/tail, asymptomatic PM_RCC, and an interval after initial nephrectomy >2 were favorable prognostic factors for the overall survival after initial nephrectomy for RCC. Conclusions: Pancreatectomies for PM_RCC can achieve long-term survival whenever complete resection is feasible, with acceptable complication rates. Patients with left kidney RCC, body/tail, and asymptomatic PM_RCC and an interval of more than 2 years after nephrectomy exhibit the best survival rates.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Long-term outcomes after surgical resection of pancreatic metastases from renal Clear-cell carcinoma

Cited by 2 publications

References 35 publications

A pooled analysis of pancreatic resection for metastatic renal cell carcinoma

A pooled analysis of pancreatic resection for metastatic renal cell carcinoma

Surgery for an Uncommon Pathology: Pancreatic Metastases from Renal Cell Carcinoma—Indications, Type of Pancreatectomy, and Outcomes in a Single-Center Experience

Contact Info

Product

Resources

About